Method for providing sustained antiepileptic therapy

• US 6,287,598 B1
• Filed: 05/28/1993
• Issued: 09/11/2001
• Est. Priority Date: 05/28/1993
• Status: Expired due to Fees

• Current Assignee: Encinal Pharmaceutical Investments, LLC
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Ayer, Atul Devatt, Yieh, Richard L.-C., Wong, Patrick S.-L., Pollock, Brenda J.
• Primary Examiner(s): Webman, Edward J.
• Application Number:
  US08/069,069
• Time in Patent Office: 3,028 Days
• Field of Search: 424/473, 424/468-472, 424/457-462, 424/449, 514/964-965
• US Class Current: 424/468
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

This invention pertains to a dosage form for the management of epilepsies wherein the dosage form comprises administering valproic acid or a valproic acid derivative at a continuous rate over an extended time.

Claims

1. A method for administering an antiepileptic drug to the gastrointestinal tract of humans, wherein the method comprises:

(a) admitting orally into the human a dosage form comprising 10 nanograms to 750 milligrams of an antiepileptic drug selected from the group consisting of valproic acid, valproic acid salts, sodium valproate, potassium valproate, calcium valproate, valpromide, valproic ester, divalproex sodium, oligomer salt of valproic acid, prodrug of valproic acid, and pharmaceutically acceptable derivatives of valproic acid;

which drug possessing antiepileptic therapy is administered from a dosage form comprising a member selected from the group consisting of a sustained-release dosage form and a controlled-release dosage form; and

,

(b) administering the antiepileptic drug from the dosage form over a therapeutic dose up to 750 mg over an extended period of time up to 30 hours to provide the antiepileptic therapy.

2. A method for administering an antiepileptic drug to the gastrointestinal trace of a human, wherein the method comprises:

(a) admitting orally into the human a dosage form comprising 10 nanograms to 750 milligrams of a member selected from the group consisting of one to three moles of valproic acid and one to six moles of a salt of valproic acid;

an oligomer of valproic acid salt, and valproic acid containing four moles of the salt and the acid;

three moles of valproic acid and calcium valproate;

valproic acid and sodium valproate;

valproic acid and divalproex sodium and calcium valproate and valpromide;

which drug possessing antiepileptic therapy is administered from a dosage form comprising a member selected from the group consisting of a sustained-release dosage form and a controlled-release dosage form; and

,

(b) administering the antiepileptic drug from the dosage form over a therapeutic dose up to 750 mg over an extended period of time up to 30 hours to provide the antiepileptic therapy.